Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration.
暂无分享,去创建一个
Christopher J Roberts | Vladimir I Razinkov | C. Roberts | Dingjiang Liu | V. Razinkov | Richard L Remmele | Dingjiang Liu | Erik J Fernandez | Nayoung Kim | R. Remmele | E. Fernandez | Nayoung Kim
[1] C. Winsor,et al. The Gompertz Curve as a Growth Curve. , 1932, Proceedings of the National Academy of Sciences of the United States of America.
[2] Erinc Sahin,et al. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. , 2011, International journal of pharmaceutics.
[3] Sandeep Kumar,et al. Potential aggregation prone regions in biotherapeutics , 2009, mAbs.
[4] Jochem Alsenz,et al. Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.
[5] William F. Weiss,et al. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. , 2012, Journal of pharmaceutical sciences.
[6] Massimo Morbidelli,et al. Population balance modeling of antibodies aggregation kinetics. , 2012, The journal of physical chemistry. B.
[7] C. Roberts,et al. Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. , 2011, Journal of pharmaceutical sciences.
[8] David C. James,et al. Therapeutic proteins : methods and protocols , 2005 .
[9] Babatunde A. Ogunnaike,et al. Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. , 2010, Journal of pharmaceutical sciences.
[10] V. Subramaniam,et al. Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .
[11] Glyn L. Devlin,et al. Amyloid fibril-like structure underlies the aggregate structure across the pH range for beta-lactoglobulin. , 2009, Biophysical journal.
[12] Yi Li,et al. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. , 2011, Journal of pharmaceutical sciences.
[13] Christopher J Roberts,et al. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions. , 2011, Journal of pharmaceutical sciences.
[14] Theodore W Randolph,et al. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. , 2009, Journal of pharmaceutical sciences.
[15] S. Cohen,et al. Antibody structure , 2006 .
[16] C. Roberts,et al. Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. , 2007, Biochemistry.
[17] Theodore W Randolph,et al. Aggregation of a monoclonal antibody induced by adsorption to stainless steel , 2010, Biotechnology and bioengineering.
[18] Sandeep Yadav,et al. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. , 2010, Journal of pharmaceutical sciences.
[19] A. Lenhoff,et al. A consistent experimental and modeling approach to light-scattering studies of protein-protein interactions in solution. , 2005, Biophysical journal.
[20] A. Grillo,et al. Conformational origin of the aggregation of recombinant human factor VIII. , 2001, Biochemistry.
[21] Etienne Weiss,et al. Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.
[22] Liqiang Lisa Zhou,et al. Impact of short range hydrophobic interactions and long range electrostatic forces on the aggregation kinetics of a monoclonal antibody and a dual-variable domain immunoglobulin at low and high concentrations. , 2011, International journal of pharmaceutics.
[23] A. Vermeer,et al. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.
[24] Deborah S. Goldberg,et al. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.
[25] W. Gombotz,et al. Minimization of recombinant human Flt3 ligand aggregation at the Tm plateau: a matter of thermal reversibility. , 1999, Biochemistry.
[26] Christopher J Roberts,et al. Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. , 2011, Journal of pharmaceutical sciences.
[27] William F. Weiss,et al. Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. , 2009, Journal of pharmaceutical sciences.
[28] Huub Schellekens,et al. Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.
[29] M. Shirts,et al. Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange , 2011, Pharmaceutical Research.
[30] Colleen E. Price,et al. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.
[31] Yatin R. Gokarn,et al. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. , 2010, Journal of pharmaceutical sciences.
[32] Hollis Lau,et al. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. , 2010, Biochemistry.
[33] Erinc Sahin,et al. Relating particle formation to salt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A. , 2012, Journal of pharmaceutical sciences.
[34] C. Roberts,et al. Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. , 2009, The journal of physical chemistry. B.
[35] Heather Franey,et al. Increased aggregation propensity of IgG2 subclass over IgG1: Role of conformational changes and covalent character in isolated aggregates , 2010, Protein science : a publication of the Protein Society.
[36] A. Fink. Protein aggregation: folding aggregates, inclusion bodies and amyloid. , 1998, Folding & design.
[37] Vincenzo Martorana,et al. Aggregation of a multidomain protein: A coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress , 2010, Protein science : a publication of the Protein Society.
[38] Wei Wang,et al. Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.
[39] Wei Wang,et al. Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.
[40] John F. Carpenter,et al. Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.
[41] Christopher J Roberts,et al. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. , 2010, Journal of pharmaceutical sciences.
[42] Massimo Morbidelli,et al. On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. , 2012, Biophysical chemistry.
[43] Wei Wang,et al. Protein aggregation and its inhibition in biopharmaceutics. , 2005, International journal of pharmaceutics.
[44] Pieter Bastiaan Ober. Random Phenomena: Fundamentals of Probability and Statistics for Engineers , 2011 .
[45] Christopher J Roberts,et al. Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.
[46] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[47] William F Weiss,et al. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.
[48] Ruth C. Carter,et al. Principles , 2003, Law’s Reality.
[49] A. Ginsburg. Reversible, Thermally Induced Domain Unfolding in Oligomeric Proteins. Spectral and DSC measurements , 2000 .
[50] Yi Li,et al. Reexamining protein-protein and protein-solvent interactions from Kirkwood-Buff analysis of light scattering in multi-component solutions. , 2011, The Journal of chemical physics.
[51] M. Manning,et al. Aggregation of recombinant human interferon gamma: kinetics and structural transitions. , 1998, Journal of pharmaceutical sciences.
[52] Linda O Narhi,et al. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. , 2011, Journal of pharmaceutical sciences.
[53] Huub Schellekens,et al. Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[54] S. Demarest,et al. A broad range of Fab stabilities within a host of therapeutic IgGs. , 2007, Biochemical and biophysical research communications.
[55] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[56] Theodore W Randolph,et al. Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. , 2009, Biochemistry.
[57] P. Privalov. Stability of proteins: small globular proteins. , 1979, Advances in protein chemistry.
[58] Theodore W Randolph,et al. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. , 2002, Biochemistry.